IP Verse

Incyte Corporation opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Incyte Corporation

Patent Number:
EP3450434
Title:
Deuterated Derivatives Of Ruxolitinib
Applicant:
CONCERT PHARMACEUTICALS INC.
Opposition Date:
Nov 23, 2021

Latest patents of Incyte Corporation opposed by its competitors

Patent:
EP2919766
Grant Date:
May 26, 2021
Title:
Sustained-Release Dosage Forms Of Ruxolitinib
Oppositions:
4
Patent:
EP2671882
Grant Date:
Feb 21, 2018
Title:
Pyrrolo[2,3-B]Pyridin-4-Yl-Amines And Pyrrolo[2M3-B]Pyrimidin-4-Yl-Amines As Janus Kinase Inhibitors
Oppositions:
1
Patent:
EP2300455
Grant Date:
Jul 19, 2017
Title:
Salts Of 2-Fluoro-N-Methyl-4-[7-(Quinolin-6-Yl-Methyl) - Imidazo [1, 2-B] [1, 2, 4] Triazin-2-Yl] Benzamide And Processes Related To Preparing The Same
Oppositions:
1

Competitors of Incyte Corporation

ALFRED E. TIEFENBACHER (GMBH & CO. KG)

CONCERT PHARMACEUTICALS INC.

CONCERT PHARMACEUTICALS, INC.

Want to track Incyte Corporation?

Feel free to send us a message here and we will get back to you